Share the Video:

Studying psychedelics, safety, and risk Q&A

PS2025

Natalie Gukasyan, Abigail Calder, Benjamin Hatten, Wesley Ryan, Patil Armenian

A comprehensive understanding of the safety and potential risks of psychedelic-assisted therapy is crucial for its responsible advancement. This session will critically analyze adverse events reported across clinical trials of various psychedelic compounds and therapeutic uses. By examining the nature, frequency, and severity of these events, the panelists will provide a clearer picture of the risk-benefit profile of this emerging treatment approach and the lessons researchers might carry forward into future clinical research.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.